Innovation in CNS Disease Research
Diseases of the central nervous system represent one of the major public health challenges today. Despite our increasing knowledge of neurobiology and improvement in treatments, there remains significant need for new medicines which offer higher levels of efficacy and reduced potential for side effects.
Our experience
The development of new treatment options for CNS diseases is a key priority for Boehringer Ingelheim.
At our research and development center for CNS Diseases in Germany our scientists, together with our academic and industry partners, are pursuing novel therapeutic approaches to address unmet needs across a range of neuropsychiatric diseases.
Our research focus
Our approach focuses on investigating maladaptive brain circuitry underlying major untreated neuropsychiatric symptoms:
- Cognition focusing on episodic, working memory and/or cognitive control
- Positive valence focusing on anhedonia/motivation
- Negative valence focusing on loss/sustained threat
In addition, investigations of pathological trajectories in adolescence, in conjunction with emerging genetic data, are applied to find ways for early intervention of neuropsychiatric disorders.
We are optimistic that these approaches, through better understanding of brain circuitry, will lead to the development of effective treatments that can be applied across mental illness.
Our commitment to CNS research never stops
Central Nervous System diseases, including schizophrenia, depression and Alzheimer’s disease, are a focus of Boehringer Ingelheim discovery research and development. We have several compounds in development, some in advanced clinical phases. Making progress is a challenge, and we may face setbacks along the way, but we remain hopeful that with time we can, and will, find effective solutions to devastating brain disorders. We have hope to transform the lives of people living with brain disorders. Our Commitment Never Stops.